Literature DB >> 16954167

Novel pan-DR-binding T cell epitopes of adenovirus induce pro-inflammatory cytokines and chemokines in healthy donors.

Lianne M Haveman1, Marc Bierings, Elisabeth Legger, Mark R Klein, Wilco de Jager, Henny G Otten, Salvatore Albani, Wietse Kuis, Alessandro Sette, Berent J Prakken.   

Abstract

Adenovirus can cause fatal infections in the immunocompromised host. To date, no effective anti-viral therapy is available. Adoptive therapy with adenovirus-specific T cells could be a promising treatment, but requires the identification of such T cells. Aim of this study was to identify conserved adenoviral T cell epitopes recognized in a majority of healthy individuals. By using a computer algorithm designed to predict pan-HLA-DR-binding T cell epitopes, we selected 19 peptides of adenovirus serotype 5. PBMCs from 26 healthy subjects were isolated and incubated with these peptides to test epitope-specific T cell proliferation. Six epitopes derived from E1B protein, hexon protein (two epitopes), DNA polymerase, E3A glycoprotein and fiber protein induced a proliferative T cell response in the majority of healthy controls. In vitro MHC binding assays confirmed the potential capacity of the adenovirus epitopes to bind multiple MHC alleles. The cytokine and chemokine profile induced by these epitopes was determined with a multiplex immunoassay and revealed a predominant pro-inflammatory pattern. Based on the broad recognition and the induced cytokine and chemokine profile, the detected epitopes can be regarded as potential candidates to select adenovirus-specific T cells for immune intervention in the immunocompromised host.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954167     DOI: 10.1093/intimm/dxl085

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  T-cell response to viral antigens in adults and children with common variable immunodeficiency and specific antibody deficiency.

Authors:  L M Haveman; J Scherrenburg; L J Maarschalk-Ellerbroek; P D Hoek; R Schuurman; W de Jager; P M Ellerbroek; B J Prakken; D van Baarle; J M van Montfrans
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

2.  Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.

Authors:  Dionisia Quiroga; Yasser A Aldhamen; Sarah Godbehere; Laura Harding; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

Review 3.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

4.  IL17eScan: A Tool for the Identification of Peptides Inducing IL-17 Response.

Authors:  Sudheer Gupta; Parul Mittal; Midhun K Madhu; Vineet K Sharma
Journal:  Front Immunol       Date:  2017-10-31       Impact factor: 7.561

5.  A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection.

Authors:  Marcus Vinícius Alves-Silva; Dirlei Nico; Alexandre Morrot; Marcos Palatnik; Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2017-02-23       Impact factor: 7.561

6.  Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.

Authors:  Victor Cervera-Carrascon; Dafne C A Quixabeira; Riikka Havunen; Joao M Santos; Emma Kutvonen; James H A Clubb; Mikko Siurala; Camilla Heiniö; Sadia Zafar; Teija Koivula; Dave Lumen; Marjo Vaha; Arturo Garcia-Horsman; Anu J Airaksinen; Suvi Sorsa; Marjukka Anttila; Veijo Hukkanen; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther Oncolytics       Date:  2020-03-19       Impact factor: 7.200

Review 7.  Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.

Authors:  Ahmed Elkashif; Marwa Alhashimi; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Clin Transl Immunology       Date:  2021-10-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.